Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A .2021 .a cancer journal for clinicians. Global cancer statistics, 71 : 209-49.
Cathomas R,Lorch A,Bruins HM,Compérat EM,Cowan NC,Efstathiou JA .2022 .The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol, 81 : 95-103.
Ślusarczyk A,Garbas K,Pustuła P,Zapała Ł,Radziszewski P .2024 .Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer. Cancers, 16 : 1684-8.
Saginala K,Barsouk A,Aluru JS,Rawla P,Padala SA,Barsouk A .2020 .Epidemiology of bladder cancer. Med Sci, 8 : 15-9.
Holzbeierlein JM,Bixler BR,Buckley DI,Chang SS,Holmes R,James AC .2024 .Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol, 211 : 10-97.
Lazebnik T. .2022 .Cell-level spatio-temporal model for a Bacillus Calmette-Guérin-based immunotherapy treatment protocol of superficial bladder cancer. Cells, 11 : 2372-6.
Wang Z,Han C,Xu Y,Yu X,Kang W,Xiang Y .2021 .The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical bacillus Calmette-Guérin vaccine therapy in patients with nonmuscle invasive bladder cancer. J Cancer Res Thera, 17 : 625-9.
Zaza MM,Salem TA,El-Sadat AM .2024 .Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer. Urologia J, 91 : 61-8.
Roumiguié M,Kamat AM,Bivalacqua TJ,Lerner SP,Kassouf W,Böhle A .2022 .International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol, 82 : 34-46.
Culp MB,Soerjomataram I,Efstathiou JA,Bray F,Jemal A .2020 .Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol, 77 : 38-52.
Del Giudice F,Asero V,Bologna E,Scornajenghi CM,Carino D,Dolci V .2023 .Efficacy of different bacillus of Calmette-Guérin (BCG) strains on recurrence rates among intermediate/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis. Cancers, 15 : 1937-9.
Lv M,Shang S,Liu K,Wang Y,Xu P,Song H .2024 .Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. Pharmaceutics, 16 : 1067-9.
Yu SH,Wang CY,Wang SS,Li JR,Hung SC .2024 .Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with T1 High Grade Bladder Cancer. Anticancer Res, 44 : 1299-307.
McElree IM,Steinberg RL,Mott SL,O'Donnell MA,Packiam VT .2023 .Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Guérin for the treatment of patients with high-risk non-muscleinvasive bladder cancer. JAMA Network Open, 6(2) : e230849-54.
Al-Humairi RM .2023 .Systemic interleukin-6 response after intravesical instillation of Bacillus Calmette-Guérin and mitomycin C in superficial bladder cancer. Arch Razi Institute, 78 : 353-6.
Laukhtina E,Abufaraj M,Al-Ani A,Ali MR,Mori K,Moschini M .2022 .Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus, 8 : 447-56.
Guerrero-Ramos F,González-Padilla DA,González-Díaz A,de la Rosa-Kehrmann F,Rodríguez-Antolín A,Inman BA .2022 .Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol, 40 : 999-1004.
Babjuk M,Burger M,Capoun O,Cohen D,Compérat EM,Escrig JL .2022 .European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol, 81 : 75-94.
Coleman JA,Clark PE,Bixler BR,Buckley DI,Chang SS,Chou R .2023 .Diagnosis and management of nonmetastatic upper tract urothelial carcinoma: AUA/SUO guideline. J Urol, 209 : 1071-81.